Study on Trametinib and Pembrolizumab for Treating Recurrent Non-small Cell Lung Cancer

Inclusion Criteria

• Have a confirmed diagnosis of non-small cell lung cancer (NSCLC) that is metastatic, cannot be surgically removed, or has returned after treatment.
• Have a tumor that can be biopsied and agree to undergo a biopsy before starting the study treatment.
• Have been tested for specific genetic mutations (EGFR, ALK) and have received appropriate treatments if these mutations are present.
• Have measurable disease according to standard criteria.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have adequate blood cell counts and organ function as determined by specific blood tests.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 120 days after the last dose.
• Be able to swallow and retain oral medication.
• Have previously received certain cancer treatments, including MEK inhibitors and anti-PD-1 or anti-PD-L1 therapies, and meet specific criteria for resistance or progression on these treatments.
• Agree to provide written informed consent and comply with all study procedures.

Exclusion Criteria

• Have participated in another clinical trial or used an investigational device within four weeks of starting the study treatment.
• Have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or other immunosuppressive treatments.
• Have had prior monoclonal antibody therapy within four weeks before starting the study.
• Have received previous immunomodulatory therapy and discontinued due to severe side effects.
• Have had recent chemotherapy, targeted therapy, or radiation therapy and have not recovered from side effects.
• Have another active cancer that requires treatment, except for certain non-threatening cancers.
• Have active brain metastases or cancer spread to the brain lining.
• Have active autoimmune disease requiring treatment in the past two years.
• Have lung disease or pneumonitis requiring systemic steroids.
• Have an active infection requiring treatment.
• Have symptomatic fluid buildup in the abdomen or around the lungs.
• Have a condition or treatment that might interfere with the study results or participation.
• Are pregnant or breastfeeding, or planning to become pregnant or father a child during the study.
• Have a history of HIV, active hepatitis B or C, or have received a live vaccine recently.
• Have a history of heart problems or are taking medications that affect heart rhythm.